Abstract
Get full access to this article
View all access options for this article.
References
1.U.S. Securities and Exchange Commission, Form 8-K Current Report of Editas Medicine Inc. , 2022. Available from: https://www.sec.gov/Archives/edgar/data/0001650664/000155837022000862/edit-20220207x8k.htm (Last accessed May 16 , 2022
2.
Frangoul
H
,
Altshuler
D
,
Cappellini
D
et al. CRISPR-Cas9 gene editing for sickle cell disease and β- . NEJM . 2021 ; 384 :252 –260 . DOI: 10.1056/NEJMoa2031054.
3.
Gillmore
JD
,
Gane
E
,
Taubel
J
et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis . NEJM . 2021 ; 385 :493 –502 . DOI: 10.1056/NEJMoa2107454.